ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 128 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,017,083 | -31.7% | 1,037,840 | -3.1% | 0.00% | – |
| Q2 2023 | $1,488,095 | +22.6% | 1,070,572 | +40.3% | 0.00% | – |
| Q1 2023 | $1,213,506 | -86.1% | 763,211 | -45.6% | 0.00% | -100.0% |
| Q4 2022 | $8,746,515 | +96.0% | 1,403,935 | +110.8% | 0.00% | +100.0% |
| Q3 2022 | $4,463,000 | +22.0% | 666,051 | +15.8% | 0.00% | 0.0% |
| Q2 2022 | $3,659,000 | +81.5% | 575,400 | +32.4% | 0.00% | – |
| Q1 2022 | $2,016,000 | -19.6% | 434,436 | -13.3% | 0.00% | – |
| Q4 2021 | $2,506,000 | -60.2% | 500,800 | -4.1% | 0.00% | -100.0% |
| Q3 2021 | $6,290,000 | -40.8% | 521,997 | +4.0% | 0.00% | -50.0% |
| Q2 2021 | $10,617,000 | -10.9% | 501,946 | +18.1% | 0.00% | 0.0% |
| Q1 2021 | $11,919,000 | -42.4% | 424,916 | -46.6% | 0.00% | +100.0% |
| Q4 2020 | $20,678,000 | +51.9% | 795,352 | +117.1% | 0.00% | -66.7% |
| Q3 2020 | $13,614,000 | -19.3% | 366,285 | +11.4% | 0.00% | -25.0% |
| Q2 2020 | $16,867,000 | +29.2% | 328,739 | -20.6% | 0.00% | 0.0% |
| Q1 2020 | $13,054,000 | -45.3% | 414,029 | +3.4% | 0.00% | -33.3% |
| Q4 2019 | $23,884,000 | +41.9% | 400,538 | -12.8% | 0.01% | +20.0% |
| Q3 2019 | $16,832,000 | -73.7% | 459,119 | -66.6% | 0.01% | -28.6% |
| Q2 2019 | $63,902,000 | +245.0% | 1,373,608 | +197.7% | 0.01% | -12.5% |
| Q1 2019 | $18,523,000 | +9.3% | 461,344 | +25.2% | 0.01% | +33.3% |
| Q4 2018 | $16,947,000 | -62.7% | 368,400 | -64.0% | 0.01% | -60.0% |
| Q3 2018 | $45,417,000 | +4.1% | 1,023,600 | -8.1% | 0.02% | 0.0% |
| Q2 2018 | $43,642,000 | -46.7% | 1,113,600 | -1.6% | 0.02% | -48.3% |
| Q1 2018 | $81,885,000 | +171.9% | 1,132,100 | +147.5% | 0.03% | +163.6% |
| Q4 2017 | $30,114,000 | +236.8% | 457,379 | +156.4% | 0.01% | +266.7% |
| Q3 2017 | $8,942,000 | -56.4% | 178,400 | -59.7% | 0.00% | -66.7% |
| Q2 2017 | $20,511,000 | -5.1% | 443,200 | -27.6% | 0.01% | -18.2% |
| Q1 2017 | $21,603,000 | +1216.5% | 611,800 | +366.7% | 0.01% | – |
| Q4 2016 | $1,641,000 | -51.2% | 131,083 | -46.0% | 0.00% | -100.0% |
| Q3 2016 | $3,361,000 | +32.8% | 242,668 | -5.3% | 0.00% | +100.0% |
| Q2 2016 | $2,531,000 | -53.2% | 256,144 | -19.9% | 0.00% | -66.7% |
| Q1 2016 | $5,410,000 | -10.1% | 319,954 | +18.3% | 0.00% | 0.0% |
| Q4 2015 | $6,021,000 | -71.0% | 270,512 | -69.3% | 0.00% | -70.0% |
| Q3 2015 | $20,757,000 | -72.6% | 879,900 | -4.9% | 0.01% | -68.8% |
| Q2 2015 | $75,643,000 | +1.2% | 925,182 | +14.6% | 0.03% | -5.9% |
| Q1 2015 | $74,778,000 | +9306.0% | 807,536 | +4009.8% | 0.03% | – |
| Q4 2014 | $795,000 | – | 19,649 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $99,609,000 | 22.32% |
| Bellevue Group AG | 5,465,715 | $203,160,000 | 2.81% |
| Rhenman & Partners Asset Management AB | 455,000 | $16,912,000 | 1.50% |
| Endurant Capital Management LP | 135,901 | $5,051,000 | 1.49% |
| Boxer Capital, LLC | 975,000 | $36,241,000 | 1.25% |
| DCF Advisers, LLC | 56,500 | $2,100,000 | 1.07% |
| Pentwater Capital Management LP | 2,169,022 | $80,623,000 | 1.04% |
| Nicholas Investment Partners, LP | 235,855 | $8,767,000 | 0.95% |
| Amia Capital LLP | 20,464 | $761,000 | 0.88% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,717,000 | 0.83% |